MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
23.95
-0.58
-2.36%
After Hours: 24.42 +0.47 +1.96% 18:45 12/08 EST
OPEN
24.44
PREV CLOSE
24.53
HIGH
25.10
LOW
23.92
VOLUME
913.01K
TURNOVER
0
52 WEEK HIGH
42.48
52 WEEK LOW
20.67
MARKET CAP
2.57B
P/E (TTM)
-12.4545
1D
5D
1M
3M
1Y
5Y
Arrowhead Pharmaceuticals: Transition To Commercialization
Arrowhead pharmaceuticals is transitioning from a pre-commercialization phase to a fully commercial pharmaceutical company. The company is focused on bringing candidate drugs in varied disease categories to regulatory approval. Arrowhead has shown promising results in its pulmonary drug candidates. I believe the company is a solid buy for long-term investors.
Seeking Alpha · 1d ago
Arrowhead Pharma: Current report
Press release · 3d ago
Bank of America Says the S&P 500 Will Hit a New Record High in 2024 — Here Are 2 Stocks to Play That Bullish Sentiment
TipRanks · 3d ago
Arrowhead Pharmaceuticals: Strong Buy Rating Confirmed Amidst Strategic Milestones and Robust Pipeline Progress
TipRanks · 3d ago
What 4 Analyst Ratings Have To Say About Arrowhead Pharma
Arrowhead pharma (nasdaq:arwr) has an average price target of $37.25. 4 analysts have provided ratings for arrowhead pharma in the last quarter. These analysts have an average rating of "bullish" on the stock. The current price of the stock is $23.21, implying upside.
Benzinga · 4d ago
B of A Securities Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $29
Benzinga · 4d ago
The 1-Minute Market Report December 4, 2023
Home market report: best performer last week was blockchain, as bitcoin and other cryptocurrencies continued to rally. The s&p 500 winning streak continues. The market entered a golden crossa configuration over the weekend. The monthly returns chart shows the 28% gain in the s&p 500 for 2023.
Seeking Alpha · 4d ago
Weekly Report: what happened at ARWR last week (1127-1201)?
Weekly Report · 4d ago
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and efficient modes of delivery. The Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company's pipeline includes ARO-APOC3 for Hypertriglyceridemia; ARO-ANG3 for Dyslipidemia; Olpasiran for Cardiovascular disease; ARO-ENAC2 for Cystic fibrosis; ARO-MUC5AC and ARO-RAGE for Muco-obstructive or inflammatory pulmonary conditions; ARO-MMP7 for Idiopathic pulmonary fibrosis, and GSK-4532990 for Non-alcoholic steatohepatitis (NASH). It also offers Fazirsiran for lpha-1 antitrypsin deficiency (AATD); JNJ-3989 for Chronic hepatitis B virus; ARO-DUX4 for Facioscapulohumeral muscular dystrophy; HZN-457 for Uncontrolled gout; ARO-PNPLA3 for Non-alcoholic steatohepatitis, and ARO-SOD1 for Amyotrophic lateral sclerosis.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.